"
Uiuce bus model
From 2013.igem.org
(Difference between revisions)
| Line 426: | Line 426: | ||
<li><a name="data1" >Market Analysis</a></li> | <li><a name="data1" >Market Analysis</a></li> | ||
<li><a name="data2" >Financial Plan</a></li> | <li><a name="data2" >Financial Plan</a></li> | ||
| - | <li><a name="data3" >Risk Analysis</a></li> | + | <li><a name="data3" >Past and Future Plans</a></li> |
| + | <li><a name="data4" >Vivosynth Technologies: Value Proposition</a></li> | ||
| + | <li><a name="data5" >Risk Analysis</a></li> | ||
</div> | </div> | ||
| Line 480: | Line 482: | ||
<div id="data3" style="display:none"> | <div id="data3" style="display:none"> | ||
| - | <center><h2> | + | <center><h2>Past and Projected Timeline</h2></center><br/> |
| - | <p> | + | <p>Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.</p><br><br> |
</div> | </div> | ||
| + | <div id="data5" style="display:none"> | ||
| + | <center><h2>Vivosynth Technologies: Value Proposition</h2></center><br/> | ||
| + | |||
| + | <p>Unique, significant, and adaptable product design<br> | ||
| + | Founding team with diverse backgrounds in engineering, molecular biology, and business development<br> | ||
| + | Experienced advisory board<br> | ||
| + | Logistical and technical support from the Institute for Genomic Biology</p><br><br> | ||
| + | </div> | ||
| + | |||
| + | <div id="data5" style="display:none"> | ||
| + | |||
| + | <center><h2>Risk Analysis</h2></center><br/> | ||
| + | |||
| + | <p>Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.</p><br><br> | ||
| + | </div> | ||
Revision as of 01:39, 29 October 2013
Business Model
Overview
Customer Problem
The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.
Our Solution
Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.
